ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
ImmuPharma PLC is a biopharmaceutical company developing novel peptide therapeutics.
Our pipeline is focused on two core therapeutic areas; autoimmunity & inflammation and anti-infectives.
*Phase 2/3 adaptive trial becomes a pivotal trial for filing
Our core therapeutic areas
The P140 platform
LUPUZORTM for Lupus
P140 for CIDP
for systemic fungal infections
for severe bacterial infections